Frank H Schaftenaar, Andrea D van Dam, Gerjan de Bruin, Marie A C Depuydt, Jill de Mol, Jacob Amersfoort, Hidde Douna, Menno Meijer, Mara J Kröner, Peter J van Santbrink, Mireia N A Bernabé Kleijn, Gijs H M van Puijvelde, Bogdan I Florea, Bram Slütter, Amanda C Foks, Ilze Bot, Patrick C N Rensen, Johan Kuiper
BACKGROUND: Atherosclerosis is the major underlying pathology of cardiovascular disease and is driven by dyslipidemia and inflammation. Inhibition of the immunoproteasome, a proteasome variant that is predominantly expressed by immune cells and plays an important role in antigen presentation, has been shown to have immunosuppressive effects. METHODS: We assessed the effect of ONX-0914, an inhibitor of the immunoproteasomal catalytic subunits LMP7 (proteasome subunit β5i/large multifunctional peptidase 7) and LMP2 (proteasome subunit β1i/large multifunctional peptidase 2), on atherosclerosis and metabolism in LDLr-/- and APOE*3-Leiden...
April 25, 2024: Arteriosclerosis, Thrombosis, and Vascular Biology